katanosin B: from genus Cytophaga; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 197270 |
| MeSH ID | M0159196 |
| Synonym |
|---|
| katanosin b |
| lysobactin |
| 2-amino-n-[1-[[6-(2-amino-1-hydroxy-2-oxoethyl)-15-butan-2-yl-18-[3-(diaminomethylideneamino)propyl]-12-(1-hydroxyethyl)-3-(hydroxymethyl)-24-(1-hydroxy-2-methylpropyl)-21-(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-28-phenyl-1-oxa-4,7,10,13,16,19,22 |
| katanosin |
| 116340-02-4 |
| Q910540 |
| gtpl10970 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "This review covers our recent advances in the synthesis of unusual amino acids in optically pure form, and their introduction into naturally occurring peptides with specific biological properties, or into modified bioactive peptides, aiming to obtain analogues displaying enhanced performances in term of activity, bioavailability and resistance to enzymatic hydrolysis." | ( Unusual amino acids: synthesis and introduction into naturally occurring peptides and biologically active analogues. Cardillo, G; Gentilucci, L; Tolomelli, A, 2006) | 0.33 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Technical factors included investment in the optimization of dosing for improved drug exposure, toxicological evaluation of the purified eutomer from a diastereomer and the failure to develop an effective research formulation." | ( Decision making in the pharmaceutical industry - A tale of three antibiotics. Hunt, A; Kirsch, DR, 2020) | 0.56 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (15.79%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (84.21%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||